Ponatinib

Evidence Level: L5

Predicted Indications: 2

Ponatinib

Pharmacist Assessment Report

Ponatinib: From BCR-ABL1-Positive Chronic Myelogenous Leukemia to Fibromatosis, Gingival

One-Sentence Summary

Ponatinib was originally used to treat BCR-ABL1-positive chronic myelogenous leukemia. The TxGNN model predicts it may be effective for gingival fibromatosis (top-ranked prediction), but there are currently 0 clinical trials and 0 publications supporting this direction. A second prediction, liposarcoma, has 0 clinical trials and 1 preclinical publication.

Quick Overview

Item	Content
Original Indication	Chronic myelogenous leukemia, BCR-ABL1 positive
Predicted New Indication	Fibromatosis, gingival
TxGNN Prediction Score	0.9904
Evidence Level	L5
Canada Market Status	Marketed (marketed DINs: 1 of 1)
Number of DINs	1 (marketed: 1)
Recommended Decision	Hold

Why is This Prediction Reasonable?

Currently, detailed mechanism of action data is not available in the data compiled for this report. Based on known information, ponatinib is a multi-targeted tyrosine kinase inhibitor (targeting BCR-ABL, FGFR, PDGFR, VEGFR, SRC and KIT). Its efficacy in BCR-ABL1-positive chronic myelogenous leukemia has been established, and mechanistically it may be applicable to conditions driven by kinase signaling.

For gingival fibromatosis, the only support is the high TxGNN score (0.9904). Kinase signaling in fibroblast proliferation and extracellular matrix deposition could plausibly relate to fibrotic overgrowth, but this link is speculative and not backed by clinical or literature evidence. Gingival fibromatosis is a rare and mostly benign condition, and ponatinib’s cardiovascular and vascular occlusive toxicity would be hard to justify for it.

Secondary prediction: liposarcoma (score 0.9900). Ponatinib inhibits several receptor tyrosine kinases (FGFR, PDGFR, KIT, SRC, RET) that may drive sarcoma biology. One 2017 preclinical study identified druggable kinase targets in liposarcoma. From the available information, I cannot confirm that ponatinib itself was tested or found active, so this evidence is indirect and preclinical (L4).

Clinical Trial Evidence

Currently no related clinical trials registered, for either gingival fibromatosis or liposarcoma.

Literature Evidence

For gingival fibromatosis, currently no related literature available.

For liposarcoma (secondary prediction), one publication is available:

PMID	Year	Type	Journal	Key Findings
29132397	2017	Preclinical (kinase profiling / RNAi and drug screening)	Journal of Hematology & Oncology	Kinase profiling of liposarcomas identified druggable kinase targets; liposarcoma is an understudied cancer with limited progress in treating metastatic disease

Canada Market Information

DIN	Product Name	Dosage Form	Approved Indication
02437333	ICLUSIG	Not available	Not available

Cytotoxicity

Item	Content
Cytotoxicity Classification	Targeted therapy (multi-targeted tyrosine kinase inhibitor)
Myelosuppression Risk	Please refer to the package insert warnings and precautions
Emetogenicity Classification	Please refer to the package insert warnings and precautions
Monitoring Items	Please refer to the package insert; routine monitoring typically includes CBC, liver function and cardiovascular status
Handling Protection	Please refer to the package insert warnings and precautions

Safety Considerations

Drug Interactions (100 interactions recorded; examples from the first 20 reviewed):

Major: Acetylsalicylic acid, Clarithromycin
Moderate: Loperamide, Aprepitant, Dexamethasone, Naldemedine, Naltrexone, Metronidazole, Miconazole
Minor: Famotidine, Ranitidine, Cimetidine, Nizatidine, Rabeprazole, Omeprazole, Lansoprazole, Dexlansoprazole, Pantoprazole, Magnesium oxide, Naloxegol

Warnings and contraindications from the Canadian package insert were not available in the data compiled for this report. Please refer to the package insert for them.

Conclusion and Next Steps

Decision: Hold

Rationale: The gingival fibromatosis prediction rests only on a model score, with no clinical trials or literature (L5). Ponatinib’s vascular occlusive and cardiovascular toxicity makes the risk-benefit profile unfavourable for a mostly benign condition. Liposarcoma is a more plausible research question (L4, preclinical only) but does not yet justify clinical advancement.

To proceed, the following is needed:

Health Canada package insert warnings and contraindications (a blocking gap for safety screening)
Detailed mechanism of action data (MOA)
Confirmation of whether ponatinib was specifically tested in the liposarcoma kinase screening study
Preclinical evidence (e.g., fibroblast or cell-line studies) for gingival fibromatosis
Approved indication text and dosage form for DIN 02437333
A risk-benefit assessment of cardiovascular and vascular occlusive toxicity for the proposed indications
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.